Trial Profile

A 12-Week Extension Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pemvidutide (Primary)
Indications Non-alcoholic fatty liver disease; Obesity
Focus Adverse reactions; Therapeutic Use
Sponsors Altimmune

Most Recent Events

05 Jun 2024 Results presented in the Altimmune Media Release.
05 Jun 2024 According to an Altimmune media release, data from the study were presented at the EASL International Liver Congress™ 2024 in Milan, Italy.
05 Jun 2024 According to an Altimmune media release, readouts expected in Q1 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com